Ontology highlight
ABSTRACT:
SUBMITTER: Carter BZ
PROVIDER: S-EPMC5111086 | biostudies-other | 2016 Sep
REPOSITORIES: biostudies-other
Carter Bing Z BZ Mak Po Yee PY Mu Hong H Zhou Hongsheng H Mak Duncan H DH Schober Wendy W Leverson Joel D JD Zhang Bin B Bhatia Ravi R Huang Xuelin X Cortes Jorge J Kantarjian Hagop H Konopleva Marina M Andreeff Michael M
Science translational medicine 20160901 355
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein lev ...[more]